Platinum-Resistant Ovarian CancerPhase 1NCT06964009
DT2216
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
What the film says
Ovarian cancer is usually found after it has spread across the abdomen. Chemotherapy works, then for many women stops working, and options narrow fast.
The idea: send engineered immune cells to where the cancer actually lives, the lining of the abdomen.
A woman's own T cells are fitted with a receptor for TAG72, a sugar-coated marker most ovarian cancers carry and healthy tissue mostly lacks. After chemotherapy makes room, the cells go not into a vein but through a port into the abdominal cavity, among the tumor deposits. In mice, that regional delivery beat the same cells given by vein.
This trial, at City of Hope with Lorna Rodriguez, asks first whether it is safe. Public record; not medical advice.
Sources behind this film
Usually found after spread across the abdomen; platinum resistance narrows options; Own T cells, lymphodepletion, cells given intraperitoneally; City of Hope with Lorna Rodriguez; safety and dose first
Murad JP. Front Immunol, 2018
TAG72: a sugar-coated (sialyl-Tn glycan) marker on most ovarian cancers, largely absent from healthy adult tissue; In mice, regional delivery controlled tumors far better than intravenous
The drug
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of TAG72-CAR T cells in participants with recurrent epithelial ovarian cancer (EOC). II To determine the maximum tolerated dose (MTD). III. To identify the recommended phase 2 dose (RP2D). SECONDARY OBJECTIVES: I. Persistence of CAR T cells in blood and peritoneal cavity pre- and 28 days post-infusion. II. Response based on Immune-Related Response Criteria (irRC). III.
Estimate the 6 month progression free survival rate. IV. Estimate median overall survival. V. TAG72 expression on tumor cells by immunohistochemistry (IHC) and/or flow cytometry; VI. Describe the serum cytokine profile pre- and post-CAR T cell infusion to assess potential cytokine release syndrome (CRS) toxicity and CAR T cell effector function. EXPLORATORY OBJECTIVES: I.
The study
This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant). T cells are infection fighting blood cells that can kill tumor cells.
The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells. These TAG72-specific T cells may help the body's immune system identify and kill TAG72+ cancer cells.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.